The liver plays a major role in metabolism and elimination of leukotrienes (LT). It produces cysteinyl leukotrienes (cLT), and cLT have been implicated in hepatocellular toxicity in several models of lipopolysaccharide (LPS)-associated liver injury. However, the liver cell types responsible for cLT production are poorly defined, and the expression of the LT-synthesis enzymes, 5-lipoxygenase Leukotrienes (LT), a class of proinflammatory eicosanoids, 1,2 are metabolized by the liver, 2-4 secreted into bile by an adenosine triphosphate-dependent organic anion transporter in the canalicular membrane, 5 and are associated with several models of inflammatory liver injury. 3,4 The cysteinyl leukotrienes (cLT), LTC 4 , LTE 4 , and LTD 4 , produce smooth muscle contraction and vascular permeability changes underlying diseases such as bronchial asthma, allergic rhinitis, and rheumatoid arthritis.